Loading clinical trials...
Loading clinical trials...
Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction
Conditions
Interventions
Capecitabine (Xeloda)
Locations
1
United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States
Start Date
February 1, 2000
Primary Completion Date
September 1, 2013
Completion Date
September 1, 2013
Last Updated
November 13, 2014
NCT07035587
NCT05688176
NCT05624099
NCT06027515
NCT06381583
NCT05680077
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions